Literature DB >> 19808339

Mechanisms underlying improvements in ejection fraction with carvedilol in heart failure.

Mathew S Maurer1, Jonathan D Sackner-Bernstein, Lyna El-Khoury Rumbarger, Madeline Yushak, Donald L King, Daniel Burkhoff.   

Abstract

BACKGROUND: Reductions in heart rate (HR) with beta-blocker therapy have been associated with improvements in ejection fraction (EF). However, the relative contributions of HR reduction, positive inotropism, afterload reduction, and reverse remodeling to improvements in EF are unknown. METHODS AND
RESULTS: Twenty-nine patients (63+/-12 years old) with New York Heart Association class II-III heart failure underwent serial measurements of left ventricular volumes using 3-dimensional echocardiography and blood pressures by sphygmomanometry at baseline, 2 weeks, 2, 6, and 12 months after initiation of carvedilol. From these parameters, left ventricular contractility (indexed by the end-systolic pressure-volume ratio), total peripheral resistance, and effective arterial elastance (E(a)) were derived. Overall, EF increased by 7-percentage points after 6 months of therapy (from 25+/-9 to 32+/-9, P<0.0001). This change was due to an increase in stroke volume (P<0.001) with no significant change in end-diastolic volume (P=0.15). The EF change correlated with increased contractility, decreased HR and decreased total peripheral resistance (P<0.003 in each case). In those patients whose EF increased at least 5 points, approximately 60% of the increase was due to HR reduction, approximately 30% was due to increased contractility, and <20% was due to the decrease in total peripheral resistance.
CONCLUSIONS: Decreased HR, improved chamber contractility and afterload reduction each contributed significantly to improved EF with carvedilol.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19808339     DOI: 10.1161/CIRCHEARTFAILURE.108.806240

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  24 in total

1.  Validation of noninvasive indices of global systolic function in patients with normal and abnormal loading conditions: a simultaneous echocardiography pressure-volume catheterization study.

Authors:  Raquel Yotti; Javier Bermejo; Yolanda Benito; Ricardo Sanz-Ruiz; Cristina Ripoll; Pablo Martínez-Legazpi; Candelas Pérez del Villar; Jaime Elízaga; Ana González-Mansilla; Alicia Barrio; Rafael Bañares; Francisco Fernández-Avilés
Journal:  Circ Cardiovasc Imaging       Date:  2013-10-30       Impact factor: 7.792

2.  Relation of the Myocardial Contraction Fraction, as Calculated from M-Mode Echocardiography, With Incident Heart Failure, Atherosclerotic Cardiovascular Disease and Mortality (Results from the Cardiovascular Health Study).

Authors:  Mathew S Maurer; William J H Koh; Traci M Bartz; Sirish Vullaganti; Eddy Barasch; Julius M Gardin; John S Gottdiener; Bruce M Psaty; Jorge R Kizer
Journal:  Am J Cardiol       Date:  2016-12-18       Impact factor: 2.778

3.  Can a Left Ventricular Assist Device in Individuals with Advanced Systolic Heart Failure Improve or Reverse Frailty?

Authors:  Mathew S Maurer; Evelyn Horn; Alex Reyentovich; Victoria Vaughan Dickson; Sean Pinney; Deena Goldwater; Nathan E Goldstein; Omar Jimenez; Sergio Teruya; Jeff Goldsmith; Stephen Helmke; Melana Yuzefpolskaya; Gordon R Reeves
Journal:  J Am Geriatr Soc       Date:  2017-09-21       Impact factor: 5.562

Review 4.  Echocardiographic assessment of pressure volume relations in heart failure and valvular heart disease: using imaging to understand physiology.

Authors:  P Green; S Kodali; M B Leon; M S Maurer
Journal:  Minerva Cardioangiol       Date:  2011-08       Impact factor: 1.347

5.  Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction.

Authors:  Shannon M Dunlay; Véronique L Roger; Susan A Weston; Ruoxiang Jiang; Margaret M Redfield
Journal:  Circ Heart Fail       Date:  2012-08-30       Impact factor: 8.790

6.  Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS).

Authors:  Taslima Bhuiyan; Stephen Helmke; Ayan R Patel; Frederick L Ruberg; Jeff Packman; Kin Cheung; Donna Grogan; Mathew S Maurer
Journal:  Circ Heart Fail       Date:  2010-12-29       Impact factor: 8.790

7.  Changes in collagen metabolism account for ventricular functional recovery following beta-blocker therapy in patients with chronic heart failure.

Authors:  Miho Fukui; Akiko Goda; Kazuo Komamura; Ayumi Nakabo; Mitsuru Masaki; Chikako Yoshida; Shinichi Hirotani; Masaaki Lee-Kawabata; Takeshi Tsujino; Toshiaki Mano; Tohru Masuyama
Journal:  Heart Vessels       Date:  2014-10-29       Impact factor: 2.037

8.  Validation of Noninvasive Measures of Left Ventricular Mechanics in Children: A Simultaneous Echocardiographic and Conductance Catheterization Study.

Authors:  Shahryar M Chowdhury; Ryan J Butts; Carolyn L Taylor; Varsha M Bandisode; Karen S Chessa; Anthony M Hlavacek; Girish S Shirali; G Hamilton Baker
Journal:  J Am Soc Echocardiogr       Date:  2016-03-26       Impact factor: 5.251

9.  Longitudinal measures of deformation are associated with a composite measure of contractility derived from pressure-volume loop analysis in children.

Authors:  Shahryar M Chowdhury; Ryan J Butts; Carolyn L Taylor; Varsha M Bandisode; Karen S Chessa; Anthony M Hlavacek; Arni Nutting; Girish S Shirali; G Hamilton Baker
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2018-05-01       Impact factor: 6.875

10.  Regional mapping of myocardial hibernation phenotype in idiopathic end-stage dilated cardiomyopathy.

Authors:  Vincenzo Lionetti; Marco Matteucci; Marco Ribezzo; Dario Di Silvestre; Francesca Brambilla; Silvia Agostini; Pierluigi Mauri; Luigi Padeletti; Alessandro Pingitore; Luisa Delsedime; Mauro Rinaldi; Fabio A Recchia; Angela Pucci
Journal:  J Cell Mol Med       Date:  2014-01-20       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.